ANAVEX 2-73 Shown to Block Oxidative Stress, Preventing Onset of Alzheimer’s Disease

Data presented at Neuroscience 2012 Vancouver, BC — October 18, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today unveiled more promising new data regarding ANAVEX 2-73, the company’s drug candidate for the treatment and modification of Alzheimer’s disease currently in human clinical trials. The confidential status of the new ANAVEX 2-73 data has been…